Search

Your search keyword '"Seema A. Bhat"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Seema A. Bhat" Remove constraint Author: "Seema A. Bhat" Publisher american society of hematology Remove constraint Publisher: american society of hematology
28 results on '"Seema A. Bhat"'

Search Results

1. Ventricular arrhythmias and sudden death events following acalabrutinib initiation

4. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

8. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

9. Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

10. Hypertension and incident cardiovascular events following ibrutinib initiation

11. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome

12. Characterization of Residual CLL Following Long-Term Bruton Tyrosine Kinase Inhibitor Therapy

13. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

14. Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

15. Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy

16. Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

17. Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

18. Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

19. Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

20. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

21. A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

22. Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

23. Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

24. Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

25. Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

26. LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

27. Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

28. Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Catalog

Books, media, physical & digital resources